Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Adherence | 30 | 2024 | 389 | 9.640 |
Why?
|
| Medicare Part C | 11 | 2024 | 35 | 5.600 |
Why?
|
| Motivational Interviewing | 7 | 2023 | 46 | 4.840 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2022 | 716 | 3.860 |
Why?
|
| Hypertension | 12 | 2023 | 1284 | 3.790 |
Why?
|
| Hyperlipidemias | 5 | 2022 | 174 | 3.350 |
Why?
|
| Smoking Cessation | 7 | 2016 | 197 | 2.720 |
Why?
|
| Diabetes Mellitus | 9 | 2023 | 850 | 2.640 |
Why?
|
| Atrial Fibrillation | 5 | 2024 | 626 | 2.260 |
Why?
|
| Antihypertensive Agents | 5 | 2021 | 396 | 1.910 |
Why?
|
| Smoking | 8 | 2016 | 1031 | 1.890 |
Why?
|
| Anticoagulants | 4 | 2024 | 580 | 1.850 |
Why?
|
| United States | 38 | 2025 | 10657 | 1.620 |
Why?
|
| Medicare | 14 | 2024 | 422 | 1.610 |
Why?
|
| Aged | 42 | 2025 | 19180 | 1.570 |
Why?
|
| Retrospective Studies | 43 | 2025 | 16081 | 1.450 |
Why?
|
| Medicare Part D | 2 | 2021 | 17 | 1.430 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 1877 | 1.310 |
Why?
|
| Pharmaceutical Services | 3 | 2021 | 35 | 1.240 |
Why?
|
| Rivaroxaban | 2 | 2024 | 55 | 1.120 |
Why?
|
| Factor Xa Inhibitors | 2 | 2024 | 64 | 1.100 |
Why?
|
| Pyridones | 2 | 2024 | 112 | 1.080 |
Why?
|
| Markov Chains | 2 | 2024 | 83 | 1.080 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2024 | 105 | 1.070 |
Why?
|
| Varenicline | 2 | 2016 | 14 | 1.030 |
Why?
|
| Bupropion | 2 | 2016 | 27 | 1.020 |
Why?
|
| Antipsychotic Agents | 6 | 2024 | 373 | 1.020 |
Why?
|
| Hypoglycemic Agents | 3 | 2024 | 429 | 1.020 |
Why?
|
| Stroke | 2 | 2024 | 958 | 0.990 |
Why?
|
| Angiotensin Receptor Antagonists | 6 | 2023 | 121 | 0.990 |
Why?
|
| Pyrazoles | 2 | 2024 | 305 | 0.960 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2023 | 210 | 0.960 |
Why?
|
| Breast Neoplasms | 10 | 2023 | 2478 | 0.930 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 502 | 0.920 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 1237 | 0.920 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 92 | 0.910 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2021 | 15 | 0.910 |
Why?
|
| Humans | 77 | 2025 | 123292 | 0.890 |
Why?
|
| Obesity | 6 | 2023 | 2235 | 0.860 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2019 | 715 | 0.850 |
Why?
|
| Aged, 80 and over | 14 | 2024 | 6390 | 0.840 |
Why?
|
| Warfarin | 2 | 2022 | 118 | 0.780 |
Why?
|
| Female | 53 | 2025 | 65634 | 0.780 |
Why?
|
| Texas | 14 | 2024 | 3558 | 0.770 |
Why?
|
| Students | 3 | 2013 | 254 | 0.770 |
Why?
|
| Administration, Oral | 5 | 2024 | 671 | 0.740 |
Why?
|
| Logistic Models | 11 | 2021 | 1799 | 0.740 |
Why?
|
| Male | 44 | 2025 | 60350 | 0.720 |
Why?
|
| Drug Therapy, Combination | 5 | 2024 | 1146 | 0.720 |
Why?
|
| Hemorrhage | 1 | 2024 | 458 | 0.710 |
Why?
|
| Middle Aged | 27 | 2025 | 26095 | 0.690 |
Why?
|
| Students, Pharmacy | 2 | 2019 | 63 | 0.670 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2024 | 92 | 0.660 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 114 | 0.660 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 74 | 0.650 |
Why?
|
| Weight Gain | 3 | 2024 | 400 | 0.650 |
Why?
|
| Benchmarking | 1 | 2020 | 132 | 0.640 |
Why?
|
| Cancer Survivors | 2 | 2018 | 199 | 0.620 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 103 | 0.610 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 219 | 0.600 |
Why?
|
| Hospitalization | 3 | 2020 | 1737 | 0.570 |
Why?
|
| Health Care Costs | 1 | 2020 | 366 | 0.560 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 309 | 0.560 |
Why?
|
| Cross-Sectional Studies | 15 | 2025 | 3385 | 0.540 |
Why?
|
| Patient Readmission | 1 | 2020 | 367 | 0.540 |
Why?
|
| Drug Combinations | 4 | 2020 | 266 | 0.520 |
Why?
|
| Arabs | 1 | 2015 | 29 | 0.510 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 81 | 0.510 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 34 | 0.510 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 44 | 0.500 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 88 | 0.490 |
Why?
|
| Tobacco Products | 1 | 2015 | 61 | 0.490 |
Why?
|
| Universities | 3 | 2013 | 127 | 0.490 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 131 | 0.480 |
Why?
|
| Primary Health Care | 1 | 2021 | 754 | 0.470 |
Why?
|
| Adult | 27 | 2025 | 29093 | 0.460 |
Why?
|
| Schizophrenia | 1 | 2016 | 299 | 0.430 |
Why?
|
| Telephone | 3 | 2019 | 110 | 0.420 |
Why?
|
| Health Behavior | 1 | 2015 | 382 | 0.410 |
Why?
|
| Pharmacists | 3 | 2020 | 84 | 0.410 |
Why?
|
| Social Perception | 1 | 2013 | 57 | 0.400 |
Why?
|
| Medicaid | 3 | 2024 | 243 | 0.400 |
Why?
|
| Risk-Taking | 2 | 2012 | 92 | 0.390 |
Why?
|
| Young Adult | 13 | 2025 | 8871 | 0.380 |
Why?
|
| Nicotine | 1 | 2013 | 141 | 0.380 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2016 | 10 | 0.370 |
Why?
|
| Buprenorphine | 2 | 2022 | 92 | 0.360 |
Why?
|
| Social Class | 2 | 2024 | 190 | 0.330 |
Why?
|
| Physicians | 4 | 2019 | 581 | 0.320 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 258 | 0.310 |
Why?
|
| Disease Management | 1 | 2012 | 516 | 0.300 |
Why?
|
| Patient Compliance | 2 | 2015 | 469 | 0.300 |
Why?
|
| Blood Glucose | 4 | 2024 | 1124 | 0.290 |
Why?
|
| Hydrocodone | 2 | 2019 | 35 | 0.290 |
Why?
|
| Adolescent | 15 | 2024 | 19129 | 0.290 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2024 | 24 | 0.290 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 254 | 0.290 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 764 | 0.280 |
Why?
|
| Body Mass Index | 6 | 2024 | 1550 | 0.270 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 1304 | 0.270 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 403 | 0.260 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 595 | 0.250 |
Why?
|
| Polypharmacy | 1 | 2005 | 40 | 0.250 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5061 | 0.250 |
Why?
|
| Risk Factors | 8 | 2024 | 10033 | 0.240 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 22 | 0.240 |
Why?
|
| Aromatase Inhibitors | 3 | 2020 | 76 | 0.230 |
Why?
|
| Dabigatran | 1 | 2024 | 27 | 0.230 |
Why?
|
| Thalidomide | 1 | 2024 | 36 | 0.230 |
Why?
|
| Delirium | 1 | 2024 | 47 | 0.220 |
Why?
|
| Ambulatory Care | 2 | 2020 | 378 | 0.220 |
Why?
|
| Confidence Intervals | 3 | 2013 | 279 | 0.220 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 135 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1119 | 0.210 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 176 | 0.210 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2022 | 10 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2024 | 1169 | 0.200 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 169 | 0.200 |
Why?
|
| Health Status Disparities | 1 | 2024 | 221 | 0.200 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 417 | 0.200 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2022 | 59 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 524 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 1008 | 0.190 |
Why?
|
| Cognition Disorders | 1 | 2005 | 555 | 0.190 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 100 | 0.190 |
Why?
|
| Pharmacies | 1 | 2021 | 13 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2024 | 528 | 0.180 |
Why?
|
| Pharmacy | 1 | 2021 | 13 | 0.180 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 3681 | 0.180 |
Why?
|
| Health Surveys | 2 | 2012 | 243 | 0.180 |
Why?
|
| HIV Infections | 3 | 2023 | 1860 | 0.180 |
Why?
|
| Comorbidity | 2 | 2016 | 1497 | 0.180 |
Why?
|
| Age Factors | 3 | 2025 | 2808 | 0.180 |
Why?
|
| Tamoxifen | 2 | 2020 | 363 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2022 | 196 | 0.180 |
Why?
|
| Odds Ratio | 3 | 2013 | 1245 | 0.180 |
Why?
|
| Controlled Substances | 2 | 2019 | 12 | 0.180 |
Why?
|
| Metformin | 1 | 2022 | 147 | 0.180 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 15 | 0.180 |
Why?
|
| Neomycin | 1 | 2020 | 37 | 0.170 |
Why?
|
| Lactulose | 1 | 2020 | 39 | 0.170 |
Why?
|
| Sex Factors | 2 | 2019 | 1261 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2022 | 828 | 0.170 |
Why?
|
| Sexual Behavior | 2 | 2013 | 243 | 0.170 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 60 | 0.170 |
Why?
|
| Acute Pain | 1 | 2019 | 21 | 0.160 |
Why?
|
| Military Personnel | 2 | 2013 | 209 | 0.160 |
Why?
|
| Forecasting | 1 | 2021 | 354 | 0.160 |
Why?
|
| Psychological Theory | 2 | 2016 | 35 | 0.160 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 458 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 164 | 0.160 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 329 | 0.160 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 560 | 0.150 |
Why?
|
| Intention | 2 | 2016 | 91 | 0.150 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 216 | 0.150 |
Why?
|
| Quinolines | 1 | 2019 | 95 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 419 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 71 | 0.150 |
Why?
|
| Standard of Care | 1 | 2018 | 129 | 0.150 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1414 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2019 | 6033 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2019 | 285 | 0.140 |
Why?
|
| Chronic Pain | 1 | 2019 | 127 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2019 | 448 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 280 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2021 | 1172 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 179 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2022 | 644 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1231 | 0.140 |
Why?
|
| Perception | 2 | 2022 | 220 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 174 | 0.140 |
Why?
|
| Middle East | 2 | 2016 | 34 | 0.140 |
Why?
|
| Smoking Prevention | 1 | 2016 | 37 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2023 | 818 | 0.130 |
Why?
|
| Recurrence | 1 | 2020 | 1419 | 0.130 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 32 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 25 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2020 | 1389 | 0.130 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 63 | 0.130 |
Why?
|
| Linear Models | 1 | 2017 | 669 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 501 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 427 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2018 | 4692 | 0.120 |
Why?
|
| Cholinergic Antagonists | 2 | 2024 | 51 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2019 | 1327 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 747 | 0.110 |
Why?
|
| Propylene Glycol | 1 | 2013 | 8 | 0.110 |
Why?
|
| Child | 8 | 2024 | 24269 | 0.100 |
Why?
|
| Social Values | 1 | 2013 | 47 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 55 | 0.100 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2013 | 57 | 0.100 |
Why?
|
| Pakistan | 1 | 2012 | 75 | 0.100 |
Why?
|
| Jordan | 1 | 2012 | 8 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2013 | 93 | 0.100 |
Why?
|
| India | 1 | 2012 | 217 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 349 | 0.100 |
Why?
|
| Focus Groups | 1 | 2013 | 201 | 0.100 |
Why?
|
| Opiate Substitution Treatment | 2 | 2022 | 22 | 0.100 |
Why?
|
| Sunlight | 1 | 2011 | 23 | 0.100 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 595 | 0.090 |
Why?
|
| Overweight | 1 | 2014 | 358 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 493 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 383 | 0.090 |
Why?
|
| Self Report | 1 | 2014 | 517 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 116 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 71 | 0.090 |
Why?
|
| Cholesterol | 2 | 2023 | 528 | 0.090 |
Why?
|
| Vitamin D | 1 | 2011 | 159 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 260 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2022 | 12176 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2398 | 0.080 |
Why?
|
| Drug and Narcotic Control | 2 | 2019 | 18 | 0.080 |
Why?
|
| Incidence | 1 | 2015 | 3055 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 353 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 865 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3236 | 0.060 |
Why?
|
| New England | 1 | 2004 | 12 | 0.060 |
Why?
|
| Child Psychiatry | 1 | 2024 | 16 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2005 | 159 | 0.060 |
Why?
|
| Aripiprazole | 1 | 2024 | 20 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 726 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2005 | 773 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2004 | 77 | 0.060 |
Why?
|
| Patient Acuity | 1 | 2023 | 63 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2005 | 268 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 157 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 371 | 0.050 |
Why?
|
| Mortality | 1 | 2004 | 228 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 38 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2024 | 176 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 375 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2022 | 61 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 37 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 96 | 0.050 |
Why?
|
| Nigeria | 2 | 2013 | 79 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 179 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 125 | 0.050 |
Why?
|
| Sexual Partners | 2 | 2013 | 85 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 2759 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 249 | 0.050 |
Why?
|
| Research | 1 | 2023 | 262 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2022 | 103 | 0.050 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 644 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2004 | 637 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 64 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1316 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 147 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 513 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 214 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 736 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 134 | 0.040 |
Why?
|
| Survival Rate | 1 | 2023 | 2005 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 754 | 0.040 |
Why?
|
| United States Government Agencies | 1 | 2016 | 5 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 791 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1211 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 867 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1100 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2016 | 138 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 47 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 129 | 0.030 |
Why?
|
| Mammography | 1 | 2015 | 113 | 0.030 |
Why?
|
| SEER Program | 1 | 2015 | 194 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2013 | 39 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 242 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 714 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 343 | 0.030 |
Why?
|
| Communication | 1 | 2016 | 514 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1398 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 93 | 0.020 |
Why?
|
| Condoms | 1 | 2010 | 48 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2010 | 192 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2024 | 13928 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 2409 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 2132 | 0.010 |
Why?
|